Boehringer Ingelheim

Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, January 17, 2023
IND, Radiopharmaceutical, Oncology, National Cancer Institute, Health, University, Lymphoma, Eli Lilly, Therapy, Merck Group, Merck, Germinal center B-cell like diffuse large B-cell lymphoma, Science, Master of Science, University Hospital Heidelberg, CD38, Organic chemistry, IPO, MD, FDA, Head, Chinese Academy of Sciences, NBE, Novo Nordisk, Boehringer Ingelheim, CSO, CD19, EGFR, RDC, Cancer, Full Life Christian Centre, Clinical trial, German Cancer Research Center, CMO, Acquisition, Doctor of Philosophy, Anti-CD19 immunotoxin, S.A, PSMA, Pharmaceutical industry, Lilly, Chemistry

MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).

Key Points: 
  • MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
  • Dr. Heeger has held senior oncology clinical development positions at both large and emerging companies for more than 15 years.
  • "He joins Full-Life as we are accelerating plans for our first targeted radiopharmaceuticals to enter clinical trials.
  • Dr. Liu has had a highly successful, 18-year career in therapeutic discovery, including at Eli Lilly and Novo Nordisk.

Foundation Medicine Announces Global Collaboration with Boehringer Ingelheim to Advance Biliary Tract Cancer Care

Retrieved on: 
Thursday, January 19, 2023
Biotechnology, Health, Oncology, Clinical Trials, Cholangiocarcinoma, MDM2, FDA, Senior, Foundation Medicine, Hope, Boehringer Ingelheim, Patient, Cancer, TP53, Comprehensive, Physician, Pharmaceutical industry, Medical imaging

“Biliary tract cancers are rare and aggressive cancers and those impacted have limited treatment options along with poor prognosis,” said Francesco di Marco, Senior Vice President, Head of Therapeutic Area Oncology, Boehringer Ingelheim.

Key Points: 
  • “Biliary tract cancers are rare and aggressive cancers and those impacted have limited treatment options along with poor prognosis,” said Francesco di Marco, Senior Vice President, Head of Therapeutic Area Oncology, Boehringer Ingelheim.
  • “At Boehringer Ingelheim, we take a diligent and broad approach in some of the most difficult, but potentially most impactful, areas of cancer.
  • “High quality, well-validated genomic testing is critical to identify biliary tract cancer patients with complex alterations like MDM2 amplifications,” said Sanket Agrawal, Chief Biopharma Business Officer, Foundation Medicine.
  • “We’re proud to partner with Boehringer Ingelheim as they advance this investigational therapy and if approved, create access to it through companion diagnostic development.”
    To learn more about Foundation Medicine and Boehringer Ingelheim’s collaboration, visit here .

Mental health focus makes Boehringer Ingelheim stand out as Global Top Employer 2023

Retrieved on: 
Tuesday, January 17, 2023
Professional Services, Mental Health, Health, Other Professional Services, Human Resources, Finance, General Health, Attention, Human, Mental health, Human resources, Certification, Family, Friends, Environment, Mental disorder, Boehringer Ingelheim, Mental, Medicine

Boehringer Ingelheim’s employer offerings do particularly stand out in the dimensions of wellbeing, work environment, as well as rewards and recognition.

Key Points: 
  • Boehringer Ingelheim’s employer offerings do particularly stand out in the dimensions of wellbeing, work environment, as well as rewards and recognition.
  • The results reflect the company’s holistic employee healthcare and wellbeing approach that, beyond its emphasis on mental health, integrates concepts of physical, social and financial health.
  • The Global Top Employers award acknowledges that,” says Dr Sven Sommerlatte, Global Head of Human Resources at Boehringer Ingelheim.
  • Boehringer Ingelheim strives to curb the stigma often experienced by people with mental health conditions as an employer and beyond.

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023: Rising Healthcare Expenditure Fuels Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Health, Pharmaceutical, Ankylosing spondylitis, Infliximab, Adalimumab, Ageing, Crohn's disease, Samsung, Psoriasis, Ulcerative colitis, Biogen, Etanercept, Amgen, Growth, Rheumatoid arthritis, Boehringer Ingelheim, Samsung Biologics, Patient, Physician, Pharmacy, Pfizer, Celltrion, Biocon, Investment, Fine chemical, Pet, Novartis

The adalimumab, infliximab and etanercept biosimilars market is segmented by product into adalimumab biosimilars, infliximab biosimilars, and Cipleumab.

Key Points: 
  • The adalimumab, infliximab and etanercept biosimilars market is segmented by product into adalimumab biosimilars, infliximab biosimilars, and Cipleumab.
  • The adalimumab biosimilars market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by product, accounting for 39.33% of the total in 2021.
  • The global adalimumab, infliximab and etanercept biosimilars market is concentrated, with a small number of large players in the market.
  • The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by product will arise in the adalimumab biosimilars market segment, which will gain $1,165.5 million of global annual sales by 2026.

Global Active Pharmaceutical Ingredients (APIs) Market Analysis/Forecast Report, 2022 & 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Health, Pharmaceutical, Disease, Ageing, Boehringer Ingelheim, Bayer, API, Stroke, Novartis, Teva Pharmaceuticals, WHO, CNS, Abbott, Degenerative disease, Biotechnology, Merchant, Infection, Immune system, Death, Teva Active Pharmaceutical Ingredients, Engineering, Diabetes, Research, CVD, 2052: A Global Forecast for the Next Forty Years, US, Active ingredient, Infarction, Essential medicines, GlaxoSmithKline, Fine chemical, Agriculture, Molecule, Orthopedic surgery, Growth, Pfizer, Cardiology, Endocrinology

The "Active Pharmaceutical Ingredients (APIs) Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Active Pharmaceutical Ingredients (APIs) Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Active Pharmaceutical Ingredients (APIs) market was at US$ 190.5 Billion in 2022 and will surpass US$ 261.3 Billion by 2027, expanding at a CAGR of 6.52 from 2022 to 2027.
  • Active Pharmaceutical Ingredients (API) of good quality is core to manufacturing effective and safe essential drugs.
  • Some prominent players in the global active pharmaceutical ingredients market are Sanofi SA, F. Hoffmann-LA Roche Ltd, Pfizer, Abbott, Bayer AG, Merck & Co. Inc, Boehringer Ingelheim Gmbh, GlaxoSmithKline Plc, Novartis AG, Eli Lilly Company, and Teva Pharmaceutical.

Patient Perspective of the Corporate Reputation of Pharma Companies, 2021-2022: Boehringer Ingelheim Ranked 1st, Sanofi 2nd and Pfizer Ranked 3rd

Retrieved on: 
Friday, January 13, 2023
Pharmacist, Janssen, Ranking, Acute exacerbation of chronic obstructive pulmonary disease, Reputation, Suggestion, State, Edition, Health, Stockholm Environment Institute US Center, Pharma, Centers for Disease Control and Prevention, AstraZeneca, Boehringer Ingelheim, Patient, COPD, COVID-19, Excellent, Medical device, Animal, Medical imaging, Fine chemical, Pharmaceutical industry, Generic drug, Ridesharing company, Pfizer

The top-three pharma companies out of 16 companies, ranked for their overall corporate reputation in 2021, as assessed by respondent respiratory-conditions patient groups familiar with the company: Boehringer Ingelheim, 1st - Sanofi, 2nd - Pfizer, 3rd.

Key Points: 
  • The top-three pharma companies out of 16 companies, ranked for their overall corporate reputation in 2021, as assessed by respondent respiratory-conditions patient groups familiar with the company: Boehringer Ingelheim, 1st - Sanofi, 2nd - Pfizer, 3rd.
  • The top-three pharma companies out of 10 companies, ranked for their overall corporate reputation in 2021, as assessed by respondent respiratory-conditions patient groups working with the company: Janssen, 1st - Sanofi, 2nd - Boehringer Ingelheim, 3rd.
  • The top-three 'big-pharma' pharma companies out of 8 companies, ranked for their overall corporate reputation in 2021, assessed by respondent respiratory-conditions patient groups working with the company: Janssen, 1st - Sanofi, 2nd - Roche, 3rd.
  • Commentaries and feedback from respondent respiratory-conditions patient groups on how pharma can improve, 2021-2022
    Profiles of the 16 companies, 2021

Indegene expands Europe presence with new center in Germany to enable life sciences companies be future ready

Retrieved on: 
Tuesday, January 10, 2023
Medicine, Boehringer Ingelheim, United States Commercial Service, Mount Everest, Fine chemical, Indegene

With this center, Indegene is further strengthening its presence in Europe to help life sciences companies fast-track digital transformation across the commercialization value chain.

Key Points: 
  • With this center, Indegene is further strengthening its presence in Europe to help life sciences companies fast-track digital transformation across the commercialization value chain.
  • Indegene’s local expert teams will work closely with clients in Germany and across Europe to provide consulting services and healthcare solutions.
  • “Germany is a key market for life sciences companies in Europe.
  • Indegene has been named a Leader in the Everest Group’s Life Sciences Commercial Services Specialists PEAK Matrix Assessment®2022.

The Corporate Reputation of Pharma Companies in Canada, 2021-2022: The Patient Perspective - The Views of 124 Patient Groups - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Pharmaceutical, COVID-19, Reputation, Fear, Government, Quality of life, Diagnosis, Ambulatory Patient Group, Boehringer Ingelheim, Patient, Research, Comment, Medicine, Excellent, Medical device, Animal, Health insurance, Pharmaceutical industry, Fine chemical, Pharma, Novartis, Pfizer

The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Canada Edition - The Views of 124 Canadian Patient Groups" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Canada Edition - The Views of 124 Canadian Patient Groups" report has been added to ResearchAndMarkets.com's offering.
  • Patient groups responding to the 'Corporate Reputation of Pharma' survey are uniquely positioned to comment on the pharma industry's performance during the pandemic.
  • The 124 Canadian patient groups responding to the 2021 'Corporate Reputation' survey rated the pharma industry more favourably for corporate reputation than their predecessors in previous years.
  • 66% of 2021's respondent Canadian patient groups stated that the industry had an "Excellent" or "Good" corporate reputation, against 44% saying the same in 2020.

Corporate Reputation of Global Pharma Companies, 2021-2022: Get The Patient Perspective from 2,150 Patient Groups - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
General Health, Health, Science, Pharmaceutical, Research, MSD, Sun Pharma, Janssen, Merck, Gilead Sciences, Mylan, ViiV Healthcare, Boehringer Ingelheim, Patient, Research, Comment, VH, Merck & Co., COVID-19, Pharmaceutical industry, Lithium, Generic drug, Pharma, Novartis, Pfizer

The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Global Edition" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Global Edition" report has been added to ResearchAndMarkets.com's offering.
  • The 'Corporate Reputation of Pharma' survey is now in its 11th year, and two years into the Covid-19 pandemic.
  • Patient groups responding to 2021's 'Corporate Reputation of Pharma' survey are uniquely positioned to comment on the pharma industry's performance during the pandemic.
  • Continue reading for details on:
    How the analyst measures pharma's corporate reputation from a patient perspective;
    The headline results of the 2021 Global survey;
    The companies included in the 2021 analysis; and
    The profiles of 2021's respondent patient groups.

Patient Perspective of the Corporate Reputation of Pharma in 2021-2022: The Views of 121 Respiratory Conditions Patient Groups - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Pharmaceutical, Pharmacist, Janssen, Ranking, Acute exacerbation of chronic obstructive pulmonary disease, Reputation, Suggestion, State, Edition, Health, Stockholm Environment Institute US Center, Pharma, Centers for Disease Control and Prevention, AstraZeneca, Boehringer Ingelheim, Patient, COPD, COVID-19, Excellent, Medical device, Animal, Medical imaging, Fine chemical, Pharmaceutical industry, Generic drug, Ridesharing company, Pfizer

The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Respiratory Edition - The Views of 121 Respiratory Conditions Patient Groups" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Respiratory Edition - The Views of 121 Respiratory Conditions Patient Groups" report has been added to ResearchAndMarkets.com's offering.
  • Patient groups- and respiratory-conditions patient groups especially possess a deep and unique understanding of the patients they represent and express the collated views of these patients.
  • The report provides details on:
    How the analyst measures pharma's corporate reputation from a patient perspective;
    The companies included in the 2021 respiratory-conditions analysis;
    The headline results of the 2021 survey, from the perspective of respiratory-conditions patient groups; and
    The profiles of 2021's respondent respiratory-conditions patient groups.
  • Relationships that respondent respiratory-conditions patient groups have with pharma, 2021
    Industry-wide findings for respiratory conditions, 2021
    Rankings of 16 pharma companies, 2021 v. 2020, as assessed by respondent respiratory-conditions patient groups familiar with the companies
    Rankings of 10 pharma companies, 2021 v. 2020, as assessed by respondent respiratory-conditions patient groups working with the companies
    Rankings of 10 'big-pharma' companies, 2021 v. 2020, as assessed by respondent respiratory-conditions patient groups familiar with the companies
    Rankings of 8 'big-pharma' companies, 2021 v. 2020, as assessed by respondent respiratory-conditions patient groups working with the companies
    Profiles of the 16 companies, 2021 (v. 2020)
    I. Profiles of respondent respiratory-conditions patient groups, 2021
    II.